相关实验视频
Updated: Jan 6, 2026

07:25
Transdermal Measurement of Glomerular Filtration Rate in Mice
Published on: October 21, 2018
23.1K
与SGLT2i在IgA脏病中的芬二的有效性和安全性
Yanhong Guo1, Silu Zhao1, Yanna Dong1
1Department of Nephropathy, the First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, Henan, China.
概括
结合芬瑞和-葡萄糖共传输体-2 抑制剂 (SGLT2i) 疗法显著降低了IgA脏病患者的蛋白尿症,比单独治疗更有效. 这种组合可以保持功能,并显示出良好的安全性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 免疫球蛋白A脏病 (IgA脏病) 是一种主要的淋巴细胞疾病,其特征是介质IgA沉积.
- 蛋白尿是IgA脏病进展的关键指标,也是治疗干预的目标.
- -葡萄糖携带载体-2 抑制剂 (SGLT2i) 和芬是慢性脏疾病的新兴疗法,包括IgA脏病.
研究的目的:
- 在IgA脏病患者中,比较组合疗法 (费内伦+SGLT2i) 与单一疗法 (费内伦或SGLT2i) 的疗效和安全性.
- 评估这些治疗策略对蛋白尿和功能的影响.
- 评估安全概况,包括高血症发病率.
主要方法:
- 对76名IgA脏病患者 (2023-2024) 的回顾性研究.
- 患者被分为三个组:费内伦+SGLT2i (n=26),费内伦单疗法 (n=32) 和SGLT2i单疗法 (n=18).
- 在3个月和6个月评估尿蛋白与肌素比率 (UPCR) 和估计的淋巴球过率 (eGFR) 的变化;评估过血和不良事件.
主要成果:
- 与单一疗法相比,组合疗法在3个月和6个月内显示出明显更大的蛋白尿减少 (UPCR) (P <0.05).
- 更多的组合治疗患者在6个月内实现了≥50%的UPCR减少 (53.8%vs25.0%和22.2%,P=0.033).
- 功能 (eGFR) 在所有组中保持稳定;高血症的发病率相似,没有严重的不良事件.
结论:
- 与单一治疗相比,结合芬龙-SGLT2i疗法提供了优越和快速的蛋白尿减少IgA脏病.
- 这种组合疗法可以保持功能,并表现出良好的安全性.
- 芬龙加上SGLT2i代表了一种有前途的治疗策略,用于管理IgA脏病.
相关概念视频
Acute Kidney Injury IV: Diagnostic Studies and Prevention
238
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
238
Renal Failure: Dose Adjustments
396
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
396
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Factors Affecting Renal Clearance: Renal Impairment
394
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
394
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
214
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214
Renal Clearance
2.3K
The glomerular filtration rate (GFR) is a critical marker of kidney function, reflecting the efficiency of filtration by the glomeruli. Renal clearance of specific substances, such as inulin or creatinine, is commonly used to measure GFR.
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
2.3K

